Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry

Basit Öğe Kaydı
dc.authorscopusid15724627900
dc.authorscopusid57225151908
dc.authorscopusid56875260600
dc.authorscopusid57204450042
dc.authorscopusid55578288000
dc.authorscopusid53865075100
dc.authorscopusid57221126888
dc.contributor.authorAlibaz-Öner, Fatma
dc.contributor.authorKelesoglu, Bahar
dc.contributor.authorBalci, Mehmet Ali
dc.contributor.authorYardimci, Gözde Kübra
dc.contributor.authorArmağan, Berkan
dc.contributor.authorKiliç, Levent
dc.contributor.authorKarakaş, Özlem
dc.date.accessioned2024-09-25T19:45:15Z
dc.date.available2024-09-25T19:45:15Z
dc.date.issued2024
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractObjective Glucocorticoids (GC) are widely accepted as the standard first-line treatment for giant cell arteritis (GCA). However, relapse rates are reported up to 80% on GC-only protocol arms in controlled trials of tocilizumab and abatacept in 12-24 months. Herein, we aimed to assess the real-life relapse rates retrospectively in patients with GCA from Turkey. Methods We assembled a retrospective cohort of patients with GCA diagnosed according to ACR 1990 criteria from tertiary rheumatology centres in Turkey. All clinical data were abstracted from medical records. Relapse was defined as any new manifestation or increased acute-phase response leading to the change of the GC dose or use of a new therapeutic agent by the treating physician. Results The study included 330 (F/M: 196/134) patients with GCA. The mean age at disease onset was 68.9±9 years. The most frequent symptom was headache. Polymyalgia rheumatica was also present in 81 (24.5%) patients. Elevation of acute phase reactants (ESR>50 mm/h or CRP>5 mg/l) was absent in 25 (7.6%) patients at diagnosis. Temporal artery biopsy was available in 241 (73%) patients, and 180 of them had positive histopathological findings for GCA. For remission induction, GC pulses (250-1000 methylprednisolone mg/3-7 days) were given to 69 (20.9%) patients, with further 0.5-1 mg/kg/day prednisolone continued in the whole group. Immunosuppressives as GC-sparing agents were used in 252 (76.4%) patients. During a follow-up of a median 26.5 (6-190) months, relapses occurred in 49 (18.8%) patients. No confounding factor was observed in relapse rates. GC treatment could be stopped in only 62 (23.8%) patients. Additionally, GC-related side effects developed in 64 (24.6%) patients, and 141 (66.2%) had at least one Vasculitis Damage Index (VDI) damage item present during follow-up. Conclusion In this first multi-centre series of GCA from Turkey, we observed that only one-fifth of patients had relapses during a mean follow-up of 26 months, with 76.4% given a GC-sparing IS agent at diagnosis. At the end of follow-up, GC-related side effects developed in one-fourth of patients. Our results suggest that patients with GCA had a low relapse rate in real-life experience of a multi-centre retrospective Turkish registry, however with a significant presence of GC-associated side effects during follow-up. © 2024 Clinical and Experimental Rheumatology S.A.S.. All rights reserved.en_US
dc.identifier.doi10.55563/clinexprheumatol/zr7s0g
dc.identifier.endpage821en_US
dc.identifier.issn0392-856X
dc.identifier.issue4en_US
dc.identifier.pmid37976117en_US
dc.identifier.scopus2-s2.0-85191899080en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage816en_US
dc.identifier.urihttps://doi.org/10.55563/clinexprheumatol/zr7s0g
dc.identifier.urihttps://hdl.handle.net/20.500.12491/12926
dc.identifier.volume42en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherClinical and Experimental Rheumatology S.A.S.en_US
dc.relation.ispartofClinical and Experimental Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectgiant cell arteritisen_US
dc.subjectglucocorticoid sparing agentsen_US
dc.subjectglucocorticoidsen_US
dc.subjectrelapse rateen_US
dc.titleLow relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registryen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu